Regulation of follicle development and novel approaches to ovarian stimulation for IVF

Human Reproduction Update

Volumn 6, Issue 4, 2000, Pages 307-312

  Macklon, N S ^a   Fauser, B C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Follicle development; GnRH antagonists; IVF; Ovarian stimulation

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

ARTICLE; ATRESIA; CELL MATURATION; CELL SELECTION; CELL STIMULATION; CONTROLLED STUDY; ESTROGEN RELEASE; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN CELL; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0033837798     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/6.4.307     Document Type: Article

References (64)

1. Ovarian hyperstimulation syndrome: Modern concepts in pathophysiology and management
2. Hormonal profile during follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix)
3. A model for follicular selection and ovulation: Lessons from superovulation
4. The selection of the follicle of the month
5. Healthy and atretic human follicles in the preovulatory phase: Differences in evolution of follicular morphology and steroid content of follicular fluid
6. GnRH antagonists: New tools versus old habits
7. Ovulation induction, infertility, and ovarian cancer risk
8. Embryo transfer and multiple gestation
9. Morphological and endocrinological studies on follicular development during the human menstrual cycle
10. High dose gonadotrophin-releasing hormone antagonist (Ganerelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization
11. A pilot study involving minimal ovarian stimulation for in vitro fertilization by extending the 'FSH window' without luteal support: Initiation of low-dose recombinant follicle stimulating hormone in the with late follicular phase administration of the gonadotrophin-releasing hormone antagonist cetrorelix (Cetrotide)
12. Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation
13. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
14. Time to revolutionize ovarian stimulation
15. The pathophysiology of ovarian hyperstimulation syndrome-views and ideas
16. New data on follicle cells in polycystic ovaries: A proposed mechanism for the genesis of cystic follicles
17. Follicular development and oocyte maturation in hypogonadotrophic women employing recombinant FSH. The role of oestrogens
18. Recombinant human FSH: A new era in the development of drugs for stimulation of ovarian function
19. Manipulation of human ovarian function: Physiological concepts and clinical consequences
20. Minimal ovarian stimulation for IVF: Appraisal of potential benefits and drawbacks
21. Pregnancies and birth resulting from in vitro fertilization: French national registry, analysis of data 1986 to 1990
22. Bilan FIVNAT 1995
23. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle
24. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation
25. Evolution of the diameters of the largest healthy and atretic follicles during the human menstrual cycle
26. Dynamics of follicular growth in the human: A model from preliminary results
27. Regulation of ovarian follicular development in primates: Facts and hypothesis
28. Measurement of dimeric inhibin B throughout the human menstrual cycle
29. Ultrasonics of ovarian changes undergoing gonadotrophin stimulation
30. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human
31. Hypothalamic gonadotropin-releasing, hormone secretion and follicle-stimulating hormone dynamics during the luteal-follicular transition
32. Gonadotropin-releasing hormone antagonists: Effects on the ovarian follicle and corpus luteum
33. Superovulation strategy before in vitro fertilization
34. The dominant ovarian follicle
35. Low dose exogenous FSH initiated during the early, mid, or late follicular phase: Effects on dominant follicle development
36. Gonadal cell apoptosis
37. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in vitro fertilization patients: A prospective randomized and controlled study
38. Cryopreservation: The practicalities of evaluation
39. Morphological and functional relations of Graafian follicle growth to ovulation in women using ultrasonic, laparoscopic and biochemical measurements
40. Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides
41. Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition
42. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome
43. Follicular development during the luteal phase of the human menstrual cycle
44. Induction of ovulation for assisted reproduction programmes
45. Ontogeny of follicle-stimulating receptor gene expression in isolated human ovarian follicles
46. Friendly IVF: The way of the future?
47. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles - A pilot study
48. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist
49. The pathogenesis of the ovarian stimulation syndrome (OHS): A possible role for ovarian renin
50. Growth patterns of nondominant ovarian follicles during the normal menstrual cycle
51. Birth of a healthy female after intrcytoplasmic sperm injection of cryopreserved human oocytes
52. Lack of correlation between maximum early follicular phase serum follicle-stimulating hormone concentrations and menstrual cycle characteristics in young normo-ovulatory women
53. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: Duration rather than magnitude of FSH follicle development
54. Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: A prospective study
55. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in-vitro fertilization program: A prospective, randomized, placebo-controlled study
56. Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma. Where are we today?
57. Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients
58. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating bormone step-down regimen
59. Assisted reproductive technology in the United States and Canada: 1996 results generated from the American Society of Reproductive Medicine/Society for Assisted Reproductive Technology registry
60. Ovarian stimulation and ovarian tumours: A critical reappraisal
61. Normal human follicle development: An evaluation of correlations with oestradiol, androstenedione and progesterone levels in individual follicles
62. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome
63. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle
64. Dynamics of human follicle growth: A physiologic perspective